Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Alimta Plus Gemcitabine for Advanced Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00860015
Recruitment Status : Completed
First Posted : March 11, 2009
Results First Posted : August 25, 2020
Last Update Posted : August 25, 2020
Information provided by (Responsible Party):
Columbia University

Brief Summary:
In patients with unresectable soft tissue sarcoma, what is the response rate if treated with Alimta and gemcitabine?

Condition or disease Intervention/treatment Phase
Sarcoma, Soft Tissue Drug: Alimta Drug: Gemcitabine Phase 2

Detailed Description:
Soft tissue sarcomas represent 0.7% of all malignancies diagnosed in the United States. The peak incidence occurs in children and young adults with a second peak occurring in middle age, resulting in significant morbidity and mortality in young, productive individuals. Although limb preserving surgery and radiation therapy have improved the primary treatment of these tumors, the therapy of advanced, metastatic tumors is unsatisfactory. The purpose of this phase II study is to evaluate the efficacy of treatment with Alimta and gemcitabine given on day 1 of a 14 day cycle to patients with unresectable or metastatic soft tissue sarcomas. Gemcitabine is an established salvage therapy for soft tissue sarcomas in combination with docetaxel. Alimta is a multitargeted antifolate drug which inhibits several folate dependent enzymes required for cell proliferation. Alimta has shown efficacy in several solid tumor types both as a single agent and in combination with other agents. The combination of Alimta and gemcitabine is synergistic and is likely to have efficacy against soft tissue sarcomas. The primary objective of this study is to determine the response rate among patients with unresectable soft tissue sarcoma treated with this combination. Secondary endpoints will evaluate the median survival of this patient population, as well as time to objective tumor response, time to treatment failure and overall survival. The toxicities of this regimen in this population will also be analyzed. Given the desperate need for new agents to treat these patients, a phase II trial of this combination therapy should be pursued.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Alimta Plus Gemcitabine as Chemotherapy for Patients With Advanced Sarcoma: A Phase II Clinical
Study Start Date : August 2005
Actual Primary Completion Date : August 2009
Actual Study Completion Date : April 2012

Arm Intervention/treatment
Experimental: Alimta/Gemcitabine
IV administration of drugs for 14 days for up to 4 cycles
Drug: Alimta

500 mg/m2 via IV over 10 minutes

A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer.

Other Name: Pemetrexed

Drug: Gemcitabine

1000 mg/m2 via IV over 90 minutes

A nucleoside analog used as chemotherapy.

Other Name: Gemzar

Primary Outcome Measures :
  1. Tumor Best Response Rate [ Time Frame: Two months ]
    The best response rate will include patients with both Complete Response and Partial Response after 2 months of treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven soft tissue sarcoma (except the following histologies: gastrointestinal stromal tumors (GIST), Kaposi's Sarcoma, mesotheliomas).
  • Age ≥ 18 years
  • Recurrent or progressive disease defined as an increase in size of any existing tumor mass, or the development of new tumor mass or masses, which is not amenable to definitive surgical therapy.
  • Patients may have had another cancer but there must be convincing clinical evidence that the sarcoma is the disease requiring therapeutic intervention. (i.e. Several sarcoma patients have had had a prior cancer [Hodgkin's disease or breast cancer] treated years previously and then developed a clinically active sarcoma.)
  • Patients may have received no prior chemotherapy, or may have failed 0-2 prior cytotoxic regimens.
  • Measurable disease defined as lesions that can be measured in at least one dimension by physical examination or by means of medical imaging techniques. Ascites and pleural effusions will not be considered measurable disease.
  • Karnofsky performance status of greater than or equal to 60%.
  • At least 3 weeks since prior chemotherapy or at least 6 weeks since prior radiation therapy.

Exclusion Criteria:

  • Soft tissue sarcomas with the following histologies: gastrointestinal stromal tumors (GIST), Kaposi's sarcoma, mesotheliomas.
  • Active or uncontrolled infection
  • Prior treatment with gemcitabine or Alimta
  • Pregnant or lactating women
  • Uncontrolled central nervous system metastases
  • Inability to stop treatment with NSAIDs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00860015

Layout table for location information
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Layout table for investigator information
Principal Investigator: Robert N Taub, MD, PhD Columbia University
Layout table for additonal information
Responsible Party: Columbia University Identifier: NCT00860015    
Other Study ID Numbers: AAAB4160
First Posted: March 11, 2009    Key Record Dates
Results First Posted: August 25, 2020
Last Update Posted: August 25, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors